Category Archives: Op-Ed

Healthcare Systems in Europe "Failing Patients"

By Guest Blogger | Published: March 27, 2013
By Reflector, Brussels correspondent. Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault in Dublin, Ireland, last week, at a conference organized under the auspices of the Irish Presidency of the European Union and featuring a galaxy of Irish and European stars from [...]
Also posted in Europe, Guest Blog, healthcare | Tagged , , , , , , | 1 Comment

Social Media Guidelines: In Pursuit of a Policy

By Guest Blogger | Published: March 27, 2013
You don’t have a social media policy yet? Oh, you do, you just didn’t tell your staff? By Peter Houston. A few weeks back I wrote on this blog about the need for CEOs to get social. I’m realistic, I know that the majority of CEOs still don’t engage directly in social media. Mostly it’s “the team” [...]
Also posted in Global, Guest Blog, social media | Tagged , | 2 Comments

FTC v. Actavis: The Wrong End of the Telescope

By Guest Blogger | Published: March 25, 2013
by Traci Medford-Rosow and Peter C. Richardson On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case. The court’s grant of certiorari marked the latest chapter in a decade-long effort by the FTC to have the court rule on the festering issue of whether pay-for-delay provisions in [...]
Also posted in IP, Legal, Market Access, Regulatory, Strategy | Tagged , | 1 Comment

Good Gamification Isn't Child's Play

By Guest Blogger | Published: March 6, 2013
By Peter Houston. One of 2012’s biggest buzzwords was “Gamification” and that probably means that in 2013 there are a lot of people trying to sell you on the value of gamifying your pharma business. Excellent, there’s a lot of value in there, but before you head off to commission your own “Pharmaville” app, you should [...]
Also posted in Guest Blog, Technology, social media | Tagged , , | 2 Comments

Part D Politics: Medicare Drug Rebates or Price Controls?

By Jill Wechsler | Published: February 20, 2013
Jill Wechsler Blog – PE Feb. 22, 2013 Part D Politics:  Medicare drug rebates or price controls? While health care was barely mentioned in the recent State of the Union address, President Obama generated some interest in his proposal to cut Medicare spending by reducing “taxpayer subsidies to prescription drug companies.” That’s code for requiring pharma marketers to pay [...]
Also posted in Regulatory, healthcare, pricing | Tagged , , , , | Leave a comment